# **Data Changes for the CCDD JUNE Release Candidate 2022**

## **Based on the QA Release Generation** 20220601

|  |  |
| --- | --- |
| Data entered by | Jo-Anne Hutsul |
| Data checked by | A.Raghuveer |

## **TM File**

### **Deprecation**

The following TM concept(s) needs to be added back into the TM File with a status of **deprecated**. [Reason for deprecation].

|  |  |  |
| --- | --- | --- |
| **tm\_code** | **tm \_formal\_name** | **tm\_status** |
|  | [NONE] |  |

### **Code permanence – name changes**

The following TM concept(s) need to keep its/their existing tm\_code even though their formal name has changed. [Reason for name change].

|  |  |  |
| --- | --- | --- |
| **tm\_code (to keep)** | **tm \_formal\_name** | **tm\_code in QA Release was** |
|  | [NONE] |  |

### **Concept permanence - returns**

The following TM concept(s) is/are “missing” from the QA Release, but should come back ‘automatically’ in the Release Candidate with a status of “inactive”, when its/their supporting NTPs and MPs will be on the “Whitelist”, as their DINs have been Cancelled Post Market or are Dormant.

|  |  |
| --- | --- |
| **tm\_code** | **tm \_formal\_name** |
| 8001702 | benzalkonium and pramoxine |

## **NTP File**

### **Deprecation**

The following NTP concept(s) need to be added back into the NTP File with status of **deprecated**.

|  |  |  |  |
| --- | --- | --- | --- |
| **ntp\_code** | **ntp \_formal\_name** | **ntp\_fr\_description** | **ntp\_status** |
| 9013693 | ivacaftor 125 mg per sachet and lumacaftor 100 mg per sachet granules for oral suspension | ivacaftor 125 mg par sachet et lumacaftor 100 mg par sachet granulés pour suspension orale | Deprec |
| 9013694 | ivacaftor 188 mg per sachet and lumacaftor 150 mg per sachet granules for oral suspension | ivacaftor 188 mg par sachet et lumacaftor 150 mg par sachet granulés pour suspension orale | Deprec |
| 9014601 | ivacaftor 25 mg per sachet granules for oral suspension | ivacaftor 25 mg par sachet granulés pour suspension orale | Deprec |
| 9013569 | ivacaftor 50 mg per sachet granules for oral suspension | ivacaftor 50 mg par sachet granulés pour suspension orale | Deprec |
| 9013570 | ivacaftor 75 mg per sachet granules for oral suspension | ivacaftor 75 mg par sachet granulés pour suspension orale | Deprec |
| 9001070 | montelukast (montelukast sodium) 4 mg per sachet granules for oral suspension | montélukast (montélukast sodique) 4 mg par sachet granulés pour suspension orale | Deprec |
| 9005645 | sodium phenylbutyrate 483 mg per g granules for oral suspension | phénylbutyrate sodique 483 mg par g granulés pour suspension orale | Deprec |

### **Status update – Inactive**

The following NTP concept(s) are generating as Active but need to be set to **inactive** to align with their respective MPs.

|  |  |  |  |
| --- | --- | --- | --- |
| **ntp\_code** | **ntp \_formal\_name** | **ntp\_fr\_description** | **ntp\_status** |
| 9000881 | diazepam 2.5 mg per 0.5 mL rectal gel tube | diazépam 2,5 mg par 0,5 mL gel rectal tube | Inactive |
| 9000883 | diazepam 7.5 mg per 1.5 mL rectal gel tube | diazépam 7,5 mg par 1,5 mL gel rectal tube | Inactive |
| 9000880 | diazepam 20 mg per 4 mL rectal gel tube | diazépam 20 mg par 4 mL gel rectal tube | Inactive |

### **Code permanence – name changes**

The following NTP concepts need to keep their existing ntp\_code even though their formal name has changed.

|  |  |  |
| --- | --- | --- |
| **ntp\_code (to keep)** | **ntp \_formal\_name** | **ntp\_code in QA Release was** |
|  | [NONE] |  |

### **Concept permanence – returns check**

The following NTP concepts are “missing” from the QA Release, but should come back ‘automatically’ in the Release Candidate, when their supporting MPs will be on the “Whitelist”, as their DINs have been Cancelled Post Market or are Dormant.

|  |  |
| --- | --- |
| **ntp\_code** | **ntp \_formal\_name** |
| 9013532 | benzalkonium chloride 0.13 % and pramoxine hydrochloride 1 % cutaneous spray |
| 9013416 | buserelin (buserelin acetate) 100 mcg per actuation nasal spray |
| 9002680 | hydrocodone bitartrate 5 mg per 5 mL and phenylephrine hydrochloride 20 mg per 5 mL syrup |
| 9000231 | morphine sulfate 20 mg suppository |

## **MP File**

### **Deprecation (very rare)**

No new deprecated concepts.

### **Deprecation – manual return**

The following MP concepts need to be added back into the MP File with status of **deprecated**. For all DINs, they have had additional UoP added. All products now have new MP.

|  |  |  |  |
| --- | --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_fr\_description** | **mp\_status** |
| 00587737 | HUMULIN N (insulin isophane human 100 unit per mL suspension for injection 10 mL vial) ELI LILLY CANADA INC | HUMULIN N (insuline isophane humaine 100 unité par mL suspension injectable 10 mL fiole) ELI LILLY CANADA INC | Deprec |
| 02182971 | METHOTREXATE INJECTION USP (methotrexate (methotrexate sodium) 1000 mg per 40 mL solution for injection vial) PFIZER CANADA ULC | METHOTREXATE INJECTION USP (méthotrexate (méthotrexate sodique) 1000 mg par 40 mL solution injectable fiole) PFIZER CANADA ULC | Deprec |
| 02182777 | METHOTREXATE INJECTION USP (methotrexate (methotrexate sodium) 500 mg per 20 mL solution for injection vial) PFIZER CANADA ULC | METHOTREXATE INJECTION USP (méthotrexate (méthotrexate sodique) 500 mg par 20 mL solution injectable fiole) PFIZER CANADA ULC | Deprec |
| 02258595 | HUMIRA (adalimumab 40 mg per 0.8 mL solution for injection vial) ABBVIE CORPORATION | HUMIRA (adalimumab 40 mg par 0,8 mL solution injectable fiole) ABBVIE CORPORATION | Deprec |

### **Status update – deprecation**

The following MP concepts are generating as active but need to be set to **deprecated**. Some of these products have been assigned a new DIN, others have been discontinued. This will have to be done manually each month.

|  |  |  |
| --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_status** |
| 77700322 | METHOTREXATE INJECTION BP (methotrexate (methotrexate sodium) 1000 mg per 40 mL solution for injection vial) ACCORD HEALTHCARE INC | Deprec |
| 77700323 | METHOTREXATE INJECTION BP (methotrexate (methotrexate sodium) 500 mg per 20 mL solution for injection vial) ACCORD HEALTHCARE INC | Deprec |
| 77700627 | DIMENHYDRINATE INJECTION USP (dimenhydrinate 250 mg per 5 mL solution for injection vial) TELIP, LLC, A SUBSIDIARY OF TELIGENT, INC. | Deprec |
| 77700070 | DIASTAT (diazepam 15 mg per 3 mL rectal gel tube) BAUSCH HEALTH, CANADA INC. | Deprec |

### **Status update – Inactive**

The following MP concepts are generating as active but need to be set to **inactivated**. The DIN is still active but these particular presentations have been discontinued. *This will have to be done manually each month*.

|  |  |  |
| --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_status** |
| 77700067 | DIASTAT (diazepam 2.5 mg per 0.5 mL rectal gel tube) BAUSCH HEALTH, CANADA INC. | Inactive |
| 77700071 | DIASTAT (diazepam 20 mg per 4 mL rectal gel tube) BAUSCH HEALTH, CANADA INC. | Inactive |
| 77700069 | DIASTAT (diazepam 7.5 mg per 1.5 mL rectal gel tube) BAUSCH HEALTH, CANADA INC. | Inactive |

### **DPD descriptors**

The following concept(s) needs to have the DPD descriptor added to the brand name to allow differentiation between duplicate mp\_formal names.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| drug\_  code | mp\_code | mp\_formal\_name | DPD descriptor | DPD descriptor - FR |
|  | [NONE] |  |  |  |
|  |  |  |  |  |

### **Concept permanence – manual return**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| drug\_code | mp\_code | mp\_formal\_name | mp\_fr\_description | CCDD status |
|  | [NONE] |  |  |  |

### **Concept permanence – returns check**

The following MPs need to be added to the Whitelist to make sure that they (and their associated NTPs/TMs) continue to be present in the release:

|  |  |  |  |
| --- | --- | --- | --- |
| **drug\_code** | **mp\_code** | **mp\_formal\_name** | **DPD status** |
| 83451 | 2349191 | ALPRAZOLAM (alprazolam 0.25 mg oral tablet) SANIS HEALTH INC | Canceled post-market Expiry 2022.05.31 |
| 78360 | 2298309 | CHAMPIX (varenicline (varenicline tartrate) 0.5 mg oral tablet with varenicline (varenicline tartrate) 1 mg oral tablet) PFIZER CANADA ULC | dormant 2022.05.13 |
| 77655 | 2291177 | CHAMPIX (varenicline (varenicline tartrate) 0.5 mg oral tablet) PFIZER CANADA ULC | dormant 2022.05.13 |
| 77656 | 2291185 | CHAMPIX (varenicline (varenicline tartrate) 1 mg oral tablet) PFIZER CANADA ULC | dormant 2022.05.13 |
| 73220 | 2248849 | CORRECTOR 4 (hydroquinone 4 % cutaneous cream) VIVIER CANADA INCORPORATED | Canceled post-market Expiry 2022.06.01 |
| 66851 | 2243010 | DM EXPECTORANT (EXTRA STRENGTH) SYRUP (dextromethorphan hydrobromide 15 mg per 5 mL and guaifenesin 200 mg per 5 mL syrup) TRILLIUM HEALTH CARE PRODUCTS INC | Canceled post-market Expiry 2022.05.31 |
| 83608 | 2350890 | MORPHINE SR (morphine sulfate 30 mg prolonged-release oral tablet) SANIS HEALTH INC | Canceled post-market Expiry 2022.05.31 |
| 16635 | 2049481 | NOVAHISTEX DH (hydrocodone bitartrate 5 mg per 5 mL and phenylephrine hydrochloride 20 mg per 5 mL syrup) SANOFI-AVENTIS CANADA INC | Canceled post-market Expiry 2022.05.29 |
| 87552 | 2390051 | ONDANSETRON INJECTION, USP WITH PRESERVATIVES (ondansetron (ondansetron hydrochloride dihydrate) 2 mg per mL solution for injection 20 mL vial) MYLAN PHARMACEUTICALS ULC | Canceled post-market Expiry 2022.04.30 |
| 87549 | 77700559 | ONDANSETRON INJECTION, USP WITHOUT PRESERVATIVES (ondansetron (ondansetron hydrochloride dihydrate) 4 mg per 2 mL solution for injection ampoule) MYLAN PHARMACEUTICALS ULC | Canceled post-market  2022.05.09 |
| 87549 | 77700562 | ONDANSETRON INJECTION, USP WITHOUT PRESERVATIVES (ondansetron (ondansetron hydrochloride dihydrate) 4 mg per 2 mL solution for injection vial) MYLAN PHARMACEUTICALS ULC | Canceled post-market  2022.05.09 |
| 87549 | 77700561 | ONDANSETRON INJECTION, USP WITHOUT PRESERVATIVES (ondansetron (ondansetron hydrochloride dihydrate) 8 mg per 4 mL solution for injection ampoule) MYLAN PHARMACEUTICALS ULC | Canceled post-market  2022.05.09 |
| 87549 | 77700560 | ONDANSETRON INJECTION, USP WITHOUT PRESERVATIVES (ondansetron (ondansetron hydrochloride dihydrate) 8 mg per 4 mL solution for injection vial) MYLAN PHARMACEUTICALS ULC | Canceled post-market  2022.05.09 |
| 80442 | 2318946 | POLYSPORIN POLY TO GO (benzalkonium chloride 0.13 % and pramoxine hydrochloride 1 % cutaneous spray) JOHNSON & JOHNSON INC | Canceled post-market Expiry 2022.05.31 |
| 97496 | 2484676 | SANDOZ EFAVIRENZ/EMTRICITABINE/TENOFOVIR (efavirenz 600 mg and emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg oral tablet) SANDOZ CANADA INCORPORATED | Canceled post-market Expiry 2021.08.31 |
| 6129 | 596965 | STATEX SUPPOSITORIES 20MG (morphine sulfate 20 mg suppository) PALADIN LABS INC. | Canceled post-market Expiry 2022.05.31 |
| 43416 | 2225158 | SUPREFACT (buserelin (buserelin acetate) 100 mcg per actuation nasal spray) CHEPLAPHARM ARZNEIMITTEL GMBH | Canceled post-market Expiry 2022.05.31 |
| 77060 | 2285088 | TEVA-LISINOPRIL (TYPE P) (lisinopril 10 mg oral tablet) TEVA CANADA LIMITED | Canceled post-market Expiry 2021.06.30 |
| 77061 | 2285096 | TEVA-LISINOPRIL (TYPE P) (lisinopril 20 mg oral tablet) TEVA CANADA LIMITED | Canceled post-market Expiry 2021.06.30 |
| 77059 | 2285061 | TEVA-LISINOPRIL (TYPE P) (lisinopril 5 mg oral tablet) TEVA CANADA LIMITED | Canceled post-market Expiry 2021.01.31 |

## **Blacklist (on GitHub)**

The following changes have been made to the Blacklist for the JUNE 2022 Release Candidate. The list as it is on GitHub should be used.

Changes that have been made to the Blacklist are as follows:  
ACTION is either:

* STAY on Blacklist
* ADD to Blacklist
* REMOVE from Blacklist

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **ntp\_code** | **ntp\_formal\_name** | **drug\_code** | **mp\_code** | **mp\_formal\_name** | **ACTION** |
|  | lidocaine 0.8 % cutaneous gel | 98886 | 02499118 | AFTER SUN GEL (lidocaine 0.8 % cutaneous gel) FRUIT OF THE EARTH, INC | STAY |
| 8804964c85ad3933659c339984658081 | elexacaftor 50 mg and ivacaftor 37.5 mg and tezacaftor 25 mg oral tablet with ivacaftor 75 mg oral tablet | 101574 | 2526670 | TRIKAFTA (elexacaftor 50 mg and ivacaftor 37.5 mg and tezacaftor 25 mg oral tablet with ivacaftor 75 mg oral tablet) VERTEX PHARMACEUTICALS (CANADA) INCORPORATED | ADD |
| 3af12530e2ce18f13fa288f57da87c2c | tralokinumab 150 mg per 1 mL solution for injection syringe | 101050 | 02521288 | ADTRALZA (tralokinumab 150 mg per 1 mL solution for injection syringe) LEO PHARMA INC | REMOVE |
| 606b851ff7abfce7bcd3919886234530 | medroxyprogesterone acetate 150 mg per 1 mL suspension for injection syringe | 101256 | 02523493 | DEPO-PROVERA (medroxyprogesterone acetate 150 mg per 1 mL suspension for injection syringe) PFIZER CANADA ULC | REMOVE |
| 844fa9089f8017e22df0ee937879de55 | glecaprevir 50 mg per sachet and pibrentasvir 20 mg per sachet oral granules | 101158 | 02522470 | MAVIRET (glecaprevir 50 mg per sachet and pibrentasvir 20 mg per sachet oral granules) ABBVIE CORPORATION | REMOVE |